Phenylpropylaminopentane for Health & Longevity

Evidence Review created on 09/04/2026 using AI4L / Opus 5

Also known as: PPAP, (–)-PPAP, (2R)-PPAP, 1-phenyl-2-propylaminopentane, α,N-dipropylphenethylamine, DPPEA, MK-306

Motivation

Phenylpropylaminopentane is an experimental laboratory compound made by chemically reshaping selegiline, a prescription drug used in Parkinson’s disease. Its designers deliberately removed the enzyme-blocking action selegiline is known for and kept a second, subtler property: making nerve cells release a larger burst of dopamine and noradrenaline each time an electrical signal arrives, instead of emptying their stores at random the way older stimulants do.

That distinction is what drew attention. The Hungarian laboratory that created the compound argued that this release-amplifying signal fades steadily after young adulthood, and that restoring it might slow the loss of learning ability, drive, and vitality that follows. In rodents the compound improved learning, blunted chemically induced apathy, and worked across a wide dose range without the repetitive, agitated behaviour typical of amphetamines.

This review examines what is actually known about phenylpropylaminopentane: how it is thought to work, what the animal and laboratory record shows, how it compares with better-studied molecules in the same family, and what has never been measured. The compound has never been given to a person in a published study, and that gap frames every finding below.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Phenylpropylaminopentane

A dedicated article covering chemistry, transmitter-release enhancement, reuptake inhibition, the history of the compound’s development and abandonment, and its legal status by country.

Examine

No Examine article on phenylpropylaminopentane exists; the site search returns no results for the compound.

Examine covers dietary supplements and food-derived compounds. Phenylpropylaminopentane is an unapproved investigational drug that has never been marketed as a supplement, which is consistent with its absence from the site.

ConsumerLab

No ConsumerLab entry on phenylpropylaminopentane exists; the site search returns no results for the compound.

ConsumerLab tests commercially sold supplements and does not typically cover investigational or prescription-only pharmaceutical agents, and no consumer product containing this compound is on the regulated market to test.

Systematic Reviews

No systematic reviews or meta-analyses for Phenylpropylaminopentane were found on PubMed as of September 4, 2026.

The central trade-off for this compound — sustained catecholamine enhancement for cognition and vitality set against sympathetic overstimulation and abuse liability — is unrepresented on both sides: neither the claimed benefit nor the principal risk has been the subject of a systematic review or meta-analysis, because no human study exists to synthesise.

Mechanism of Action

Phenylpropylaminopentane is a catecholaminergic activity enhancer (CAE, a compound that increases how much transmitter a nerve cell releases per incoming electrical impulse). It was engineered from selegiline specifically to delete inhibition of monoamine oxidase B (MAO-B, the enzyme that breaks down dopamine in the brain), so that the release-enhancing action could be studied alone. In rat brain tissue the compound raises impulse-evoked dopamine and noradrenaline output without raising resting output, and this effect survives removal of every conventional explanation — enzyme inhibition, presynaptic receptor blockade, reuptake blockade, and direct transmitter displacement. The proposed proximal step is enhanced coupling between the action potential and vesicle fusion, supported by increased calcium influx in cardiac pacemaker fibres.

A competing account has since emerged. Work on the closely related compound benzofuranylpropylaminopentane (BPAP) locates the effect at trace amine-associated receptor 1 (TAAR1, a receptor inside nerve cells that senses trace amines), acting through protein kinase C (an enzyme that switches proteins on by attaching phosphate) and the vesicular monoamine transporter 2 (VMAT2, the pump that loads transmitter into storage vesicles). A third account is simple reuptake blockade: a 2026 independent screen measured half-maximal inhibitory concentrations (IC50, the concentration blocking half of a pump’s activity) of 57.5 nM at the dopamine transporter and 571 nM at the noradrenaline transporter, with negligible serotonin activity. Human half-life, tissue distribution, and metabolising enzymes have never been determined; rodent work shows uptake into catecholamine nerve terminals and, unlike selegiline, no breakdown into amphetamines.

Historical Context & Evolution

Phenylpropylaminopentane was not designed as a therapy. It was designed as a probe. József Knoll’s group at Semmelweis University had observed that selegiline activated brain dopamine systems at doses far below those needed to inhibit MAO-B, and needed a molecule that kept the first property while losing the second. The compound was first reported in 1988, characterised across the early 1990s, and published in full in 1992 as a “new spectrum psychostimulant”. Its intended use was therefore mechanistic proof, and it succeeded: because it enhanced catecholamine activity while inhibiting no enzyme, the enhancer effect could no longer be attributed to MAO-B inhibition.

Interest in health optimisation followed from a second claim by the same group: that impulse-coupled transmitter release peaks between weaning and sexual maturity and declines steadily thereafter, making its restoration a candidate longevity strategy. That claim rests on rodent lifespan work with selegiline and its successor compound, not on phenylpropylaminopentane itself.

The compound was then superseded rather than refuted. Development never reached human testing, and effort moved to the more potent successor developed with Fujimoto Pharmaceutical Corporation, which patented that molecule and had a direct financial interest in it. Cost structure reinforced the shift: selegiline is a cheap generic that insurers and national health systems already reimburse, so no institutional payer had reason to fund a novel, patent-encumbered replacement. Neither compound has since been tested in people.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human clinical endpoint and no validated clinical surrogate has ever been measured for this compound, in one trial or in several.

Medium 🟩 🟩

No benefit reaches Medium: there is no single human trial and no observational human dataset for this compound; the entire record is rodent behavioural testing and ex-vivo neurochemistry.

Low 🟩

Speculative 🟨

Learning and Retention Facilitation

Rats given the compound acquired and retained conditioned avoidance faster, reported in the original characterisation. The basis is animal behavioural work only; no human cognitive outcome has been measured.

Resistance to Chemically Induced Motivational Loss

The compound reversed learning deficits caused by transmitter-depleting tetrabenazine, most strongly in high-performing rats. Basis is rodent behaviour under pharmacological challenge, not clinical depression or apathy.

Antidepressant-Type Behavioural Activity

Activity in the forced swimming test was reported alongside the learning findings. This is a rodent screening assay with weak predictive value; no controlled human mood study exists.

Wide Effective Dose Range Without Repetitive Behaviour

Unlike amphetamine, performance improved across a broad dose band and stereotypy (repetitive, purposeless movement) was markedly weaker. Basis is rodent dose-ranging; no human tolerability or dose-response data exist.

Protection of Brain Cells Against Oxygen Deprivation

Enhancer compounds protected human brain capillary and rat nerve-model cells from oxygen deprivation. Basis is cell culture using selegiline and the successor compound; this molecule itself has never been tested.

Geroprotection via Restored Enhancer Signalling

Lifespan extension is claimed for the compound class, but the rodent longevity trials used selegiline and its successor, never this molecule. Basis is mechanistic extrapolation from related compounds only.

Benefit-Modifying Factors

Baseline catecholaminergic tone: The clearest modifier in the animal record. High-performing rats responded fully to 1 mg/kg while low-performing peers did not, suggesting benefit tracks existing transmitter output rather than compensating for a deficit.
Age at initiation: The originating hypothesis holds that impulse-coupled release peaks in early adulthood and declines afterwards, so a middle-aged or older user is predicted to have more headroom for restoration than a young one. Untested in people.
Genetic polymorphisms in dopamine clearance: COMT (an enzyme that degrades dopamine in the prefrontal cortex) Val158Met and dopamine transporter variants set synaptic dopamine availability. Slow-clearance carriers may reach an over-arousal ceiling sooner. Entirely inferred; never genotyped against this compound.
Pre-existing health conditions: Conditions marked by reduced dopaminergic drive, such as early Parkinson’s disease or post-viral fatigue, are where the mechanism would be most testable. Conversely, psychotic or bipolar spectrum illness would be expected to convert benefit into harm.
Sex-based differences: The compound’s benefit profile has never been analysed by sex. Rodent transmitter-release work included both sexes and reported the developmental release peak in males and females alike, but no sex-stratified efficacy comparison for this molecule exists.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no documented human adverse event and no validated clinical surrogate has ever been recorded for this compound, in one trial or in several.

Medium 🟥 🟥

No risk reaches Medium: there is no single human safety trial and no observational human dataset; there is not even a published case report of human exposure.

Low 🟥

Speculative 🟨

Sympathetic Cardiovascular Stimulation

Noradrenaline transporter inhibition at 571 nM was measured in vitro, predicting raised heart rate and blood pressure. Basis is transporter pharmacology and class read-across; no human haemodynamic measurement exists.

Sleep Disruption and Overstimulation

Dopamine transporter blockade at 57.5 nM is more potent than amphetamine’s, and rodent motility rose at 2 mg/kg. Insomnia, restlessness, and appetite loss are inferred from class, not observed.

Psychosis, Mania, and Severe Agitation

Potent dopamine transporter blockade is the recognised route by which stimulants precipitate paranoia, mania, or hallucination in susceptible people. Basis is class read-across only; no exposure to this compound has been observed.

Abuse and Dependence Liability ⚠️ Conflicted

The originating group reported no transmitter-releasing property and therefore no abuse liability; a 2026 transporter screen places it among stimulants. The newer independent data carry more weight.

Altered Peripheral Immune-Cell Serotonin

Serotonin content of rat monocytes, granulocytes, and mast cells rose acutely and remained raised three weeks after dosing at weaning. Basis is a single rodent study; the human consequence is unknown.

Behavioural Suppression and Toxicity at High Doses

Motility fell at 50 mg/kg in rats, the only reported high-dose signal. No lethal-dose determination, organ toxicology, or repeat-dose toxicity study has been published for any species.

Risk-Modifying Factors

Genetic polymorphisms in drug clearance: CYP2D6 and CYP2B6 (enzymes that clear many drugs from the body) handle related phenethylamines. Poor-metaboliser status could raise exposure unpredictably, but the compound’s own metabolic route has never been mapped in any species.
Baseline blood pressure and resting heart rate: The single most useful pre-existing measurement. Established hypertension or a resting heart rate above roughly 80 beats per minute would place a user closer to the ceiling of tolerable sympathetic stimulation.
Sex-based differences: No sex-stratified safety data exist. Women’s generally lower body mass and reported higher sensitivity to stimulant-induced cardiovascular effects imply a lower tolerated dose, but this is class inference, not a finding for this compound.
Pre-existing health conditions: Coronary disease, arrhythmia, uncontrolled hypertension, glaucoma, hyperthyroidism, seizure disorder, and psychotic or bipolar illness are all conditions in which catecholamine enhancement is expected to convert a modest effect into a serious one.
Age-related considerations: Older adults carry stiffer arteries, more subclinical coronary disease, and slower hepatic clearance. Since no dose has ever been established in any person, an older user has no margin of known safety to work from.

Key Interactions & Contraindications

Monoamine oxidase inhibitors (selegiline, rasagiline, phenelzine, tranylcypromine): Absolute contraindication. Blocking catecholamine breakdown while blocking reuptake and enhancing release risks hypertensive crisis. No timing separation makes this safe; the irreversible agents require a two-week washout.
Serotonergic antidepressants (serotonin reuptake inhibitors such as sertraline, dual serotonin–noradrenaline agents such as venlafaxine, tricyclics): Caution to contraindication. Additive monoamine load risks serotonin syndrome (a dangerous excess of serotonin signalling) and hypertension. No safe co-administration schedule has been established.
Other stimulants (amphetamine, methylphenidate, modafinil, high-dose caffeine): Caution. Additive dopamine and noradrenaline transporter blockade raises the risk of tachycardia, hypertension, and insomnia. Rodent work showed two-way antagonism with amphetamine on motility, so the combined effect is unpredictable.
Sympathomimetic (adrenaline-mimicking) over-the-counter medicines (pseudoephedrine, phenylephrine, oxymetazoline): Caution. Additive vasoconstriction and blood-pressure elevation. Common in decongestants and taken casually. Separating doses by at least 12 hours reduces but does not remove overlap.
Stimulant supplements (yohimbine, synephrine, higenamine, caffeine-plus-theanine pre-workouts): Caution. These act on the same adrenergic pathways and produce additive tachycardia and hypertension. They are the most likely accidental co-exposure for this audience and are best withheld entirely.
Additive dopaminergic supplements (L-Tyrosine, levodopa-containing Mucuna pruriens, β-phenylethylamine): Caution. Supplying precursor or trace amine alongside a release enhancer amplifies the same output, risking over-arousal. Reduction or omission of the supplement is the only lever, since the compound’s own dose is unknown.
CYP-inhibiting agents (fluoxetine, paroxetine, bupropion, ritonavir, grapefruit juice): Caution. These inhibit enzymes that clear structurally similar phenethylamines, plausibly raising exposure. Because the compound’s clearance route is unmapped, the size of the interaction cannot be estimated or corrected by dose reduction.
Other interventions — anaesthesia and surgery: Caution. Sympathomimetics interact with anaesthetic agents and vasopressors, and a compound absent from every drug database cannot be screened for by an anaesthetist. Disclosure and discontinuation well before any planned procedure is the only mitigation.

Populations who should avoid Phenylpropylaminopentane:

Anyone taking a monoamine oxidase inhibitor, or within 14 days of stopping an irreversible one
Uncontrolled hypertension (seated blood pressure ≥160/100 mmHg)
Established coronary artery disease, recent myocardial infarction (<12 months), or any tachyarrhythmia
Heart failure of New York Heart Association Class III or IV (marked limitation of activity, or symptoms at rest)
Structural cardiac disease or a family history of sudden cardiac death before age 50
History of psychosis, schizophrenia, or bipolar I disorder
History of stimulant, cocaine, or methamphetamine use disorder
Seizure disorder, narrow-angle glaucoma, or untreated hyperthyroidism
Moderate or severe hepatic impairment (Child-Pugh Class B or C)
Pregnancy, planned pregnancy, or breastfeeding
Anyone under 25, in whom the compound’s own developmental hypothesis predicts no headroom for enhancement

Risk Mitigation Strategies

Analytical verification before any use: Third-party mass-spectrometry identity and purity testing of the specific batch mitigates the substitution and adulteration risk that grey-market sourcing carries, where an unregulated stimulant may be supplied in place of the labelled compound.
Cardiovascular clearance first: Seated blood pressure, resting heart rate, and a 12-lead electrocardiogram before any exposure mitigate the sympathetic cardiovascular risk by excluding hypertension, arrhythmia, and QT-interval prolongation (delayed electrical recovery of the heart).
Full medication and supplement washout: Stopping monoamine oxidase inhibitors 14 days ahead and withdrawing serotonergic antidepressants, other stimulants, yohimbine, and synephrine mitigates hypertensive crisis and serotonin syndrome, the two interaction risks with lethal potential.
Lowest-possible starting exposure: Because no human dose exists, any first exposure is a dose-finding experiment. Beginning at the smallest measurable amount and holding it for several days mitigates acute overstimulation, tachycardia, and unrecognised idiosyncratic reactions.
Strict morning-only dosing: Confining exposure to before 10:00 mitigates the insomnia and sleep-architecture disruption predicted from potent dopamine transporter blockade, whose duration of action in humans is entirely unknown.
Home monitoring during any exposure period: Twice-daily blood pressure and resting heart rate readings, with a predefined stop threshold of 140/90 mmHg or a 15-beat-per-minute rise, mitigate progressive cardiovascular strain before it becomes symptomatic.
Immediate discontinuation triggers: Stopping at the first chest pain, palpitations, severe headache, agitation, or hallucination mitigates the low-probability but severe cardiac and psychiatric events that stimulant-class compounds produce without warning.

Therapeutic Protocol

No established human protocol: No clinic, practitioner, or published guideline uses this compound. It has never been administered to a person in a published study, so no dose, schedule, or duration has ever been validated.
Conventional approach — use the approved parent instead: Where a clinician pursues the same mechanism, selegiline is the licensed option with human dosing, pharmacovigilance, and reimbursement behind it. This is the approach with actual outcome data.
Investigational approach — the enhancer-dose concept: The originating Semmelweis group argued the relevant effect appears at doses far below stimulant range, using 1 mg/kg for this compound in rats and 0.001 mg/kg for selegiline. No human translation exists.
Animal reference dosing: Rodent behavioural activity was reported between 1 and 5 mg/kg subcutaneously, with motility rising at 2 mg/kg. Interspecies scaling from rodent behavioural doses to human oral doses is not reliable and no allometric conversion has been published.
Best time of day: Morning only. Potent dopamine transporter blockade and rodent motility increases both predict evening dosing would impair sleep onset. No chronopharmacology study of this compound exists.
Half-life and dose splitting: Human half-life is undetermined; even rodent pharmacokinetics were never published for this molecule. Without an elimination half-life there is no rational basis for choosing single versus split dosing, or for setting a dosing interval.
Genetic polymorphisms influencing dose: COMT Val158Met and CYP2D6 metaboliser status would be the logical stratifiers, governing prefrontal dopamine clearance and phenethylamine elimination respectively. Neither has been examined against this compound; no pharmacogenetic dose adjustment can be specified.
Sex-based differences: No sex-stratified pharmacokinetic or response data exist for this compound. Stimulant-class evidence generally shows higher exposure per milligram in women, implying any female dose should be lower, but this remains class inference.
Age-related considerations: Reduced liver clearance and stiffer arteries in adults over 65 argue for lower exposure, while the compound’s own hypothesis predicts older users gain most. These pull in opposite directions and no data resolve them.
Baseline biomarkers influencing response: The rodent finding that high-performing animals responded and low-performing ones did not implies baseline catecholaminergic tone predicts response. No human biomarker of that tone has been validated for this purpose.
Pre-existing conditions influencing response: Parkinsonian and dopamine-depleted states are where the mechanism predicts the largest effect, since the compound acts on impulse-evoked release rather than resting output. Untreated hypertension or anxiety disorder would be expected to dominate any benefit.

Discontinuation & Cycling

Intended duration: The originating hypothesis frames this compound class as lifelong prophylaxis begun in mid-life, not as short-term treatment. That framing comes from rodent lifespan work with related molecules and has never been tested in people.
Withdrawal effects: None documented, because no person has taken it under observation. Dopaminergic agents in general can produce fatigue, low mood, and increased sleep on withdrawal, so an abrupt-stop rebound is plausible but entirely unverified.
Tapering: No tapering protocol exists or can be specified without a known half-life. Where exposure has been brief and at minimal dose, gradual reduction over one to two weeks is the conservative default borrowed from stimulant practice.
Cycling for efficacy: Unaddressed in the literature. The proposed mechanism acts on release coupling rather than transmitter stores, which would argue against tolerance, but the compound’s own two-humped dose-response means higher or sustained exposure may lose effect.
Regular reassessment instead of fixed cycling: With no efficacy endpoint and no safety database, scheduled stop-and-reassess intervals of four to eight weeks substitute for a cycling rule, allowing blood pressure, sleep, and subjective effect to be judged off-compound.

Sourcing and Quality

No pharmaceutical-grade source exists: The compound is not manufactured to any pharmacopoeial standard, has no marketing authorisation anywhere, and no compounding pharmacy can legitimately prepare it. Every available source is a research-chemical vendor operating outside medicines regulation.
What to look for: A batch-specific certificate of analysis from an independent laboratory, showing identity by nuclear magnetic resonance or mass spectrometry, purity by chromatography, and residual solvent and heavy-metal screening. Vendor-supplied certificates without a named third-party laboratory carry no weight.
Formulation: Sold, where sold at all, as a raw powder or hydrochloride salt. Free-base and salt forms differ in mass per unit of active compound, and no vendor-standardised formulation exists, so label amounts are not comparable between suppliers.
Enantiomeric purity: The (–)- or (2R)-enantiomer carries the activity, and racemic material contains half inactive isomer. Certificates rarely report chiral purity, so material labelled by the parent name may be either form.
Substitution and adulteration risk: Grey-market stimulant powders are a recognised vector for substitution with cheaper cathinones or amphetamines. The absence of any reference standard in routine toxicology panels makes independent confirmation of identity difficult even when testing is attempted.
Reputable brands: None can be named. No supplier of this compound operates under third-party certification schemes, and naming vendors would imply a quality assurance that does not exist in this market.

Practical Considerations

Time to effect: Unknown in humans. Rodent transmitter-release changes appeared 30 minutes after injection, and behavioural effects within a single session, suggesting acute rather than cumulative action — but no human onset, duration, or steady-state timing has been measured.
Regulatory status: Not approved by any regulator for any indication. It is a controlled substance in Sweden and is captured by amphetamine-analogue provisions in several other jurisdictions. Possession, import, and supply may constitute an offence depending on local law.
Common pitfall — treating it as a supplement: Its absence from Examine and ConsumerLab reflects the fact that it is an unapproved drug, not that it is benign. Buyers frequently read this absence as a clean safety record.
Common pitfall — assuming selegiline’s safety record transfers: Selegiline’s decades of human data belong to selegiline. This compound differs in reuptake potency, lacks enzyme inhibition, and produces different immune-cell effects, so read-across is not justified.
Common pitfall — dose extrapolation from rodents: Converting rat milligram-per-kilogram doses directly to human milligrams overshoots by roughly six-fold on body-surface-area scaling. This is the single most likely route to accidental overexposure with an unstudied compound.
Cost and accessibility: Not exceptionally expensive as a raw powder, but genuinely difficult to obtain: few vendors stock it, batches are irregular, and independent analytical verification typically costs more than the material itself.

Interaction with Foundational Habits

Sleep: Direct and blunting. Dopamine transporter blockade more potent than amphetamine’s predicts delayed sleep onset and reduced deep sleep if exposure occurs after mid-morning. Rodent motility increases support arousal-promoting action. Practically, exposure is confined to before 10:00, and falling sleep quality is a stop signal rather than a cue to adjust.
Nutrition: Indirect and bidirectional. Stimulant-class compounds suppress appetite, risking under-eating and micronutrient shortfall over weeks. Tyrosine-rich protein supplies catecholamine precursor, so adequate protein supports the mechanism, while separate tyrosine supplements add unnecessary additive load. Tyramine-rich aged foods are less of a concern here than with selegiline, since this compound inhibits no enzyme.
Exercise: Potentiating and possibly hazardous. Adding noradrenaline reuptake blockade to exercise-driven sympathetic activation raises heart rate, blood pressure, and core temperature beyond either alone. It does not blunt hypertrophy. Practically, combining it with high-intensity or hot-environment training, or stacking it with pre-workout formulas containing caffeine, yohimbine, or synephrine, compounds that load.
Stress management: Direct and uncertain in sign. Related enhancer compounds lowered resting corticosterone in rats while leaving anxiety-like behaviour largely unchanged, hinting at stress-hormone stabilisation. Against that, heightened catecholamine tone can amplify anxiety in susceptible people. Practically, established breathwork or meditation practice provides a counterweight and a way to notice over-arousal early.

Monitoring Protocol & Defining Success

Because no human exposure has been documented, no validated monitoring protocol exists; what follows is adapted from stimulant-class practice and is intended to detect harm rather than confirm benefit. A pre-exposure baseline comprises seated blood pressure and resting heart rate on three separate mornings, a 12-lead electrocardiogram read for QT interval, a liver panel, a full blood count, and thyroid-stimulating hormone to exclude unrecognised hyperthyroidism. Two weeks of sleep and subjective energy data recorded beforehand complete it, since these change first and are the most informative early signals.

Ongoing monitoring runs blood pressure and resting heart rate twice daily for the first two weeks, then weekly. The electrocardiogram repeats at four weeks, and the liver panel and blood count at eight weeks, then every three to six months where exposure continues.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Seated blood pressure	110–125 / 65–80 mmHg	Earliest sign of sympathetic overstimulation	Taken after five minutes seated, same arm, before the morning dose; the conventional cut-off of 140/90 mmHg sits far above the point at which stimulant-class protocols stop
Resting heart rate	50–65 bpm	Tracks adrenergic load and cardiac strain	Recorded on waking, before rising; a sustained rise of 15 bpm over an individual’s own baseline is more informative than any absolute number
Corrected QT interval (QTc)	<440 ms (men), <450 ms (women)	Detects the arrhythmia risk that stimulant-class compounds can create	QTc is the heart’s electrical recovery time adjusted for rate; requires a 12-lead electrocardiogram, not a wearable; best paired with serum potassium and magnesium, which shift the interval independently
Alanine aminotransferase (ALT)	10–25 U/L (men), 8–20 U/L (women)	The compound’s clearance route is unmapped, so liver stress must be watched empirically	ALT is a liver enzyme released into blood when liver cells are stressed; conventional upper limits near 40–50 U/L are too permissive here; drawn fasting, and not within 48 hours of heavy exercise
Serum prolactin	4–15 ng/mL (men), 4–23 ng/mL (women)	Falls when central dopamine signalling rises, giving an indirect read on the intended mechanism	Drawn fasting, mid-morning, at least one hour after waking; stress and recent nipple stimulation both raise it and invalidate the sample
Thyroid-stimulating hormone	0.5–2.0 mIU/L	Excludes hyperthyroidism, which mimics and compounds stimulant side effects	Conventional range extends to 4.0–4.5 mIU/L; drawn in the morning, and best paired with free thyroxine if outside range
Fasting glucose	75–90 mg/dL	Catecholamine elevation opposes insulin action and can drift glucose upward	Requires 8–12 hours fasting; a single reading is weak evidence, so an individual’s own baseline is the more meaningful comparator than a population cut-off
Body weight	No established target; track change from the individual’s own baseline	Appetite suppression is the most likely nutritional harm and shows up as weight loss first	Recorded on waking, after voiding, on the same scale; an unintended loss exceeding 2% of body mass in a month is a stopping signal

Qualitative markers matter more here than any laboratory value, because the intended effects are subjective and the laboratory panel only detects harm.

Sleep quality: Time to fall asleep, night wakings, and whether sleep feels restorative. Deterioration is the earliest and most reliable warning sign.
Cognitive clarity: Sustained attention on a demanding task, working-memory slips, and word-finding, judged against the two-week pre-exposure record.
Energy and drive: Willingness to begin effortful tasks, distinguished carefully from restlessness or agitation, which point the opposite way.
Mood and irritability: Emotional range, tolerance for frustration, and any flattening or edginess noticed by people around the user.
Appetite: Whether meals are being skipped without hunger, an early marker of the nutritional risk above.

Emerging Research

No registered trials of the compound itself: A ClinicalTrials.gov search on 04/09/2026 returned no study of phenylpropylaminopentane in any phase, condition, or country. The registry contains nothing to follow for this molecule, and nothing is announced.
Nearest registry activity, in the parent compound: NCT07452692 is an active Phase 1 study of 232 healthy volunteers comparing skin irritation and sensitisation of a selegiline transdermal system against the reference patch. It concerns formulation, not the enhancer mechanism.
The proposed target under clinical test elsewhere: NCT07767903, a Phase 3 trial of the TAAR1 agonist ulotaront in 384 adults with generalized anxiety disorder, will show whether engaging this receptor produces clinical benefit in people at all.
Mechanism could be reassigned: Harsing et al., 2025 place the enhancer effect of the successor compound at TAAR1 rather than at action-potential coupling. If confirmed for this molecule, the original mechanistic claim that motivated four decades of work would need restating.
Reuptake data weaken the “not a stimulant” claim: Stalberga et al., 2026 quantified dopamine transporter inhibition in the stimulant range, using a modern human transporter assay where the originating group had reported the uptake block only qualitatively, in rat tissue, alongside a denial of releasing activity.
Lifespan evidence for the class is strengthening: Bene, 2025 pooled 22 rodent longevity experiments with selegiline and found a significant lifespan increase, with larger effects at higher doses and later initiation. It supports the class, not this molecule.
Tumour-manifestation finding awaits replication: Knoll et al., 2017 reported fewer spontaneous tumours in rats on enhancer compounds. Independent replication outside the originating laboratory would strengthen the case; failure to replicate would undercut the broader geroprotective claim.
Independent replication is the decisive open question: Almost every positive finding for this compound comes from one laboratory. Whether outside groups can reproduce the impulse-coupled release enhancement, using modern voltammetry, is what would move the evidence in either direction.

Conclusion

Phenylpropylaminopentane is a laboratory tool that was never meant to be a treatment. It was built to prove a point about how selegiline works, and it proved that point: brain dopamine and noradrenaline activity can be raised without blocking the enzyme selegiline blocks. Everything beyond that proof is unfinished. The compound improved learning and resisted chemically induced apathy in rats, worked across a wider dose range than amphetamine, and produced less agitated repetitive behaviour. None of this has ever been observed in a person. There is no human dose, no half-life, no safety record, and not even a published account of a single human taking it.

The evidence base is also narrow in origin. Nearly all of the favourable work comes from the Hungarian laboratory that created the compound, later joined by the pharmaceutical company that patented its successor and had a direct commercial stake in the outcome. That does not make the findings wrong, but it does mean they are largely unreplicated. Recent independent testing complicates the picture further, placing the strength of its block on dopamine recycling squarely among ordinary stimulants, which undercuts the claim that it is meaningfully unlike one.

For a reader weighing an unapproved compound, the honest summary is that the appeal rests on a mechanism that remains contested and on animal results that never carried through into human testing.

Top - Benefits - Risks - Protocol

Phenylpropylaminopentane for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Speculative 🟨

Learning and Retention Facilitation

Resistance to Chemically Induced Motivational Loss

Antidepressant-Type Behavioural Activity

Wide Effective Dose Range Without Repetitive Behaviour

Protection of Brain Cells Against Oxygen Deprivation

Geroprotection via Restored Enhancer Signalling

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Speculative 🟨

Sympathetic Cardiovascular Stimulation

Sleep Disruption and Overstimulation

Psychosis, Mania, and Severe Agitation

Abuse and Dependence Liability ⚠️ Conflicted

Altered Peripheral Immune-Cell Serotonin

Behavioural Suppression and Toxicity at High Doses

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion